Should You Buy Capricor Therapeutics Inc (CAPR) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor. While the long-term clinical story (HOPE-3 data and a path to potential mid-2026 approval) is a real upside driver, the stock is currently in a short-term downtrend with weakening momentum and extremely high options-implied volatility. With no Intellectia buy signals today and price trading below key support, the risk of near-term drawdown is high if you buy immediately.
Technical Analysis
Trend/momentum is currently bearish. CAPR is down -4.34% to 22.46 in regular trading and is trading below S1 (22.779) and close to S2 (22.017), which signals a breakdown through support and elevated downside risk if S2 fails. MACD histogram is -0.626 and negatively expanding, indicating bearish momentum is strengthening. RSI(6) is 23.338, which is oversold and can allow for a short-term bounce, but oversold readings can persist during selloffs. Moving averages are converging (no clear uptrend confirmation). Key levels: Pivot 24.013 (price needs to reclaim this to improve near-term structure), Resistance R1 25.247, R2 26.009; Support S2 22.017 is the near-term line in the sand.
Analyst Ratings and Price Target Trends
Recent analyst trend is strongly positive with rapid, clustered upgrades/target raises following HOPE-3 data: B. Riley to $50 (Buy), Piper Sandler to $45 (Overweight), Oppenheimer to $54 (Outperform), Maxim to $50 (Buy), H.C. Wainwright to $60 (Buy), Alliance Global to $48 (Buy), and Roth previously at $13 (Buy) before the Phase 3 readout.
Wall Street pros view: deramiocel’s Phase 3 efficacy and cardiac benefit increase approval odds and support large long-term sales potential (some models cite ~$1.1B risk-adjusted sales potential by 2030/2031).
Wall Street cons view: the prior FDA CRL highlights regulatory risk and timeline uncertainty; near-term share price can remain volatile and headline-driven until the FDA response/review path becomes clearer.
Trading/flows note: Hedge funds and insiders are reported neutral (no notable trend). No recent congress trading data available.
Intellectia Proprietary Trading Signals:
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Wall Street analysts forecast CAPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 51.57 USD with a low forecast of 45 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CAPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 51.57 USD with a low forecast of 45 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 21.570
Current: 21.570
